InnoCare Reports First Patient Dosed in ICP-B161 Trial in China
InnoCare says the first subject has been dosed in a China clinical trial of its TL1A/IL-23p19 bispecific antibody ICP-B161.
Related stories
China Railway Rolling Stock Corp. Q3 Revenue Falls 1.7% YoY
China Railway Rolling Stock Corp. said third-quarter revenue fell 1.7% year over year.
M impact | EQUITY | Oct 30, 2026, 09:13 AM UTC
Corey Fox Launches AEO Services for Shopify Brands
Shopify SEO consultant Corey Fox has launched AEO services for Shopify brands.
M impact | EQUITY | Oct 30, 2026, 09:12 AM UTC
Jakarta Stocks Fall 16.7% in October, Worst Since March 2020
M impact | EQUITY | Oct 30, 2026, 09:05 AM UTC
Erste Bank Polska Reports Third-Quarter Profit in Line With Expectations
Growing mortgage lending and resilient net interest income helped offset Poland’s bank tax hike, the bank said.
M impact | EQUITY | Oct 30, 2026, 09:04 AM UTC
European session market picture: S&P 500 -0.84%, Nasdaq 100 -1.95%; EUR/USD +0.15%, WTI +1.61%, LLOY leads volume
European session market picture. US index futures: S and P futures is down 0.84 percent, Nasdaq futures is down 1.95 percent, Dow futures is up 0.18 percent and Russell futures is
M impact | EQUITY | Oct 30, 2026, 09:01 AM UTC
AMD, Nvidia, Micron and Arm shares fall
AMD fell 6.5%, Nvidia 2.5%, Micron 3.7% and Arm 7.5%.
M impact | EQUITY | Oct 30, 2026, 08:59 AM UTC